Pacific Biosciences California (PACB) Stock
Developer of long-read DNA sequencing systems and consumables. Here's the price, business snapshot, and what's worth knowing about Pacific Biosciences California in October 2026.
Pacific Biosciences of California, Inc. (PACB) develops long‑read DNA sequencing systems and consumables used in genomics research and translational science. Its platforms produce high‑accuracy long reads that help assemble complex genomes, call structural variants and support applications across human genetics, agricultural genomics and drug discovery. Revenue is driven by sales of instruments, recurring consumables, service agreements and software. With a market capitalisation of about $570.70m, PACB is a small‑cap, growth‑oriented company and its shares can be volatile. Key considerations for investors include product adoption, the recurring consumable revenue stream, competitive dynamics with short‑ and long‑read sequencing rivals, and the company’s pathway to sustainable profitability. Operational risks include execution on commercial roll‑out, supply‑chain constraints and R&D outcomes. This is general educational information only and not personal investment advice; values can rise and fall and past performance does not predict future returns.
Why You’ll Want to Watch This Stock
Long‑read sequencing
Unique long‑read technology can resolve complex genomic regions and structural variants, which attracts research and clinical interest — though adoption and commercial scale‑up can take time.
Product innovation
Newer, higher‑throughput systems aim to broaden addressable markets and improve per‑sample economics, but execution and competitive responses are important risks to monitor.
Research and markets
Used across human health, pharmaceuticals and agriculture, offering diverse end markets; revenues can be cyclical and are sensitive to institutional capital spending.
